Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$19.69
0.492.55%
At close: -
$19.55
-0.14-0.71%
After Hours: May 16, 7:45 PM EDT
Comments
Loading...
ADMA Biologics Analyst Ratings and Price Targets | NASDAQ:ADMA | Benzinga
ADMA Biologics Inc has a consensus price target of $24.25 based on the ratings of 4 analysts. The high is $32 issued by Raymond James on May 8, 2025. The low is $14 issued by Mizuho on June 20, 2024. The 3 most-recent analyst ratings were released by Raymond James, Cantor Fitzgerald, and HC Wainwright & Co. on May 8, 2025, March 4, 2025, and November 8, 2024, respectively. With an average price target of $27.67 between Raymond James, Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 41.52% upside for ADMA Biologics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Raymond James
Cantor Fitzgerald
HC Wainwright & Co.
Mizuho
1calculated from analyst ratings
Analyst Ratings for ADMA Biologics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2025 | Buy Now | 63.68% | Raymond James | Elliot Wilbur45% | $25 → $32 | Maintains | Strong Buy | Get Alert |
| 03/04/2025 | Buy Now | 27.88% | Cantor Fitzgerald | Kristen Kluska68% | $25 → $25 | Reiterates | Overweight → Overweight | Get Alert |
| 11/08/2024 | Buy Now | 32.99% | HC Wainwright & Co. | Raghuram Selvaraju42% | $18 → $26 | Maintains | Buy | Get Alert |
| 11/08/2024 | Buy Now | 27.88% | Raymond James | Elliot Wilbur45% | $18 → $25 | Maintains | Strong Buy | Get Alert |
| 10/14/2024 | Buy Now | -7.93% | HC Wainwright & Co. | Raghuram Selvaraju42% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2024 | Buy Now | 2.3% | Cantor Fitzgerald | Kristen Kluska68% | $20 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 08/12/2024 | Buy Now | -7.93% | HC Wainwright & Co. | Raghuram Selvaraju42% | $10 → $18 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 2.3% | Cantor Fitzgerald | Kristen Kluska68% | $15 → $20 | Maintains | Overweight | Get Alert |
| 07/09/2024 | Buy Now | -23.27% | Cantor Fitzgerald | Kristen Kluska68% | $10 → $15 | Maintains | Overweight | Get Alert |
| 06/20/2024 | Buy Now | -28.39% | Mizuho | Anthony Petrone63% | $12 → $14 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | -48.85% | Raymond James | Elliot Wilbur45% | $8 → $10 | Maintains | Strong Buy | Get Alert |
| 05/10/2024 | Buy Now | -48.85% | Cantor Fitzgerald | Kristen Kluska68% | $8 → $10 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | -48.85% | HC Wainwright & Co. | Raghuram Selvaraju42% | $7.5 → $10 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | -38.62% | Mizuho | Anthony Petrone63% | $10 → $12 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | -61.64% | HC Wainwright & Co. | Raghuram Selvaraju42% | $6 → $7.5 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | -48.85% | Mizuho | Anthony Petrone63% | $9 → $10 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | -69.31% | HC Wainwright & Co. | Raghuram Selvaraju42% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | -59.08% | Cantor Fitzgerald | Kristen Kluska68% | $6.5 → $8 | Maintains | Overweight | Get Alert |
| 01/22/2024 | Buy Now | -53.96% | Mizuho | Anthony Petrone63% | $7 → $9 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -69.31% | HC Wainwright & Co. | Raghuram Selvaraju42% | $5 → $6 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | -69.31% | Cantor Fitzgerald | Kristen Kluska68% | $6 → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 11/17/2023 | Buy Now | -74.42% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | -69.31% | Cantor Fitzgerald | Kristen Kluska68% | $5 → $6 | Maintains | Overweight | Get Alert |
| 08/10/2023 | Buy Now | -69.31% | Raymond James | Elliot Wilbur45% | $5 → $6 | Maintains | Strong Buy | Get Alert |
| 08/10/2023 | Buy Now | -74.42% | HC Wainwright & Co. | Raghuram Selvaraju42% | $4.5 → $5 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | -76.98% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $4.5 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | -76.98% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $4.5 | Reiterates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | -76.98% | HC Wainwright & Co. | Raghuram Selvaraju42% | $4 → $4.5 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | -69.31% | Mizuho | Anthony Petrone63% | $5 → $6 | Maintains | Buy | Get Alert |
| 10/13/2022 | Buy Now | -74.42% | Mizuho | Anthony Petrone63% | → $5 | Initiates | → Buy | Get Alert |
| 07/25/2022 | Buy Now | -79.54% | HC Wainwright & Co. | Raghuram Selvaraju42% | $6 → $4 | Maintains | Buy | Get Alert |
FAQ
What is the target price for ADMA Biologics (ADMA) stock?
The latest price target for ADMA Biologics (NASDAQ:ADMA) was reported by Raymond James on May 8, 2025. The analyst firm set a price target for $32.00 expecting ADMA to rise to within 12 months (a possible 63.68% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADMA Biologics (ADMA)?
The latest analyst rating for ADMA Biologics (NASDAQ:ADMA) was provided by Raymond James, and ADMA Biologics maintained their strong buy rating.
When was the last upgrade for ADMA Biologics (ADMA)?
There is no last upgrade for ADMA Biologics
When was the last downgrade for ADMA Biologics (ADMA)?
There is no last downgrade for ADMA Biologics.
When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.
Is the Analyst Rating ADMA Biologics (ADMA) correct?
While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $25.00 to $32.00. The current price ADMA Biologics (ADMA) is trading at is $19.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
